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Summary
 
Progression to destructive insulitis in nonobese diabetic (NOD) mice is linked to the failure of
regulatory cells, possibly involving T helper type 2 (Th2) cells. Natural killer (NK) T cells
might be involved in diabetes, given their deficiency in NOD mice and the prevention of dia-
betes by adoptive transfer of 
 
a
 
/
 
b
 
 double-negative thymocytes. Here, we evaluated the role of
NK T cells in diabetes by using transgenic NOD mice expressing the T cell antigen receptor
(TCR) 
 
a
 
 chain V
 
a
 
14-J
 
a
 
281 characteristic of NK T cells. Precise identification of NK1.1
 
1
 
 T
cells was based on out-cross with congenic NK1.1 NOD mice. All six transgenic lines showed,
to various degrees, elevated numbers of NK1.1
 
1
 
 T cells, enhanced production of interleukin
(IL)-4, and increased levels of serum immunoglobulin E. Only the transgenic lines with the
largest numbers of NK T cells and the most vigorous burst of IL-4 production were protected
from diabetes. Transfer and cotransfer experiments with transgenic splenocytes demonstrated
that V
 
a
 
14-J
 
a
 
281 transgenic NOD mice, although protected from overt diabetes, developed a
diabetogenic T cell repertoire, and that NK T cells actively inhibited the pathogenic action of
T cells. These results indicate that the number of NK T cells strongly influences the develop-
ment of diabetes.
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N
 
onobese diabetic (NOD)
 
1
 
 mice develop a spontane-
ous form of type 1 diabetes very similar to the human
disease (1). Autoimmune destruction of 
 
b
 
 cells is preceded
by infiltration of pancreatic islets by macrophages and B
and T lymphocytes. The key role of T cells in diabetes de-
velopment is demonstrated by the capacity of purified T
cells or T cell clones to transfer the disease to immunoin-
competent NOD mice (2). The disease evolves in two
stages. Noninvasive insulitis begins at 3 wk of age but does
not result in destructive insulitis (at the origin of clinical di-
abetes) before 3–4 mo of age. This long period of clinically
silent insulitis and its progression to diabetes are best ex-
plained by the involvement of immunoregulatory T cells
(1). Converging data suggest that cytokine imbalance plays
a key role in the pathogenesis of diabetes, with overexpres-
sion of Th1 diabetogenic T cells relative to defective regu-
latory Th2 cells. Systemic administration of IL-4 or anti–
IFN-
 
g
 
 mAb prevents diabetes onset in NOD mice (3–5).
Conversely, IL-12, which promotes the development of
Th1 cells, accelerates disease onset in NOD mice (6). Fur-
thermore, diabetogenic T cell clones derived from NOD
mice exhibit a Th1 phenotype (7–9), and cytokine produc-
tion in the islets of NOD mice correlates with the severity
of histological lesions: IL-4–producing cells are associated
with nondestructive insulitis and IFN-
 
g
 
–producing cells
are associated with destructive insulitis (10, 11).
Recently, it has been shown that NOD mice and pa-
tients with insulin-dependent diabetes mellitus (IDDM)
have decreased numbers of NK T cells, a subset of 
 
a
 
/
 
b
 
 T
cells which express surface receptors that are normally asso-
ciated with the NK lineage (12, 13). These cells, which are
either CD4
 
1
 
 or CD4
 
2
 
CD8
 
2 
 
double-negative (DN), are
positively selected by the conserved MHC class I–like CD1
molecule and have a highly restricted TCR repertoire (14–
19). In both mice and humans, they express an invariant
TCR 
 
a
 
 chain composed of V
 
a
 
14 and J
 
a
 
281 segments in
mice, or V
 
a
 
24 and J
 
a
 
Q segments in humans (14, 17). In a
 
1
 
Abbreviations used in this paper:
 
 DN, double negative; IDDM, insulin-
dependent diabetes mellitus; NOD, nonobese diabetic; SA-APC, strepta-
vidin-allophycocyanin.
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study of twins discordant for diabetes, a correlation was ob-
served between the occurrence of IDDM and the loss of
the capacity of V
 
a
 
24-J
 
a
 
Q
 
1
 
 T cells to secrete IL-4 (13).
Similarly, in 3–6-wk-old NOD mice, IL-4 production is
markedly reduced both in vitro (thymocytes stimulated by
anti-CD3 antibody) and
 
 
 
in vivo (spleen cells after CD3 an-
tibody injection) (12). The NK T cell defect in NOD mice
might account for the deficient IL-4 production by thy-
mocytes and splenocytes from this strain (3). In nonpatho-
logical strains of mice, large amounts of IL-4 released by
NK T cells appear to favor Th2 over Th1 responses (20–
22). Therefore, this defect in NOD mice could be respon-
sible, in part, for the emergence of antiislet Th1 cells, lead-
ing to the onset of destructive insulitis and diabetes. Baxter
and colleagues have recently reported that the transfer into
3–4-wk-old NOD mice of 
 
a
 
/
 
b
 
1
 
 CD4
 
2
 
CD8
 
2
 
 double-
negative (
 
a
 
/
 
b
 
 DN) thymocytes prevented diabetes devel-
opment (23). However, because NK T cells are not the
only subset present in 
 
a
 
/
 
b
 
 DN thymocytes, it could not be
concluded that protection had been specifically mediated
by those lymphocytes. Furthermore, the fact that for tech-
nical reasons, semiallogeneic instead of syngeneic thy-
mocytes had to be inoculated raised the concern of a possi-
ble allogeneic effect being responsible for reduced disease
incidence (24).
To obtain more direct evidence in favor of a control ex-
erted by NK T cells upon diabetes, we adopted a different
strategy, consisting in generating a panel of transgenic lines
of NOD mice overexpressing the invariant TCR 
 
a
 
 chain,
V
 
a
 
14-J
 
a
 
281, of NK T cells. We observed a heterogeneous
increase in NK T cell numbers, IL-4 production, and se-
rum IgE level that varied according to the line of V
 
a
 
14-
J
 
a
 
281 transgenic mice considered. Most interestingly, the
three transgenic lines that had the largest numbers of NK T
cells were also those that manifested resistance against the
development of diabetes.
 
Materials and Methods
 
Constructs, Transgenesis, and Mice.
 
A construct coding for the
TCR 
 
a
 
 chain V
 
a
 
14-J
 
a
 
281 was used as previously described for
transgenesis of C57BL/6 mice (22). This TCR 
 
a
 
 chain was
cloned from a CD1-reactive T cell hybridoma, DN32D3 (14).
Electroeluted DNA was microinjected into fertilized NOD eggs,
and transgenic mice were identified by PCR of tail DNA, using
transgene-specific primers. We used heterozygous mice, as they
provide perfect controls within the same litters. The C
 
a
 
2
 
/
 
2
 
 mu-
tation was introduced into V
 
a
 
14-J
 
a
 
281 transgenic mice (line 86)
by two consecutive crosses with NOD C
 
a
 
2
 
/
 
2
 
 mice (a gift from
Christophe Benoist and Diane Mathis, Institut de Génétique et
de Biologie Moléculaire et Cellulaire, Illkirch, France). Trans-
genic mice homozygous for the C
 
a
 
 null mutation were first
selected by immunofluorescence of blood lymphocytes and
then confirmed by PCR typing of their progeny. Congenic
NOD.NK1.1 mice were established as a homozygous line at
backcross 10. The chromosome 6 segment containing the NK re-
ceptor complex and integrated into the NOD genome originally
derived from the C57BL/6 strain (C. Carnaud, unpublished
data). NOD scid/scid mice were originally obtained from Leo-
nard Schultz, The Jackson Laboratory (Bar Harbor, ME). All of
the strains of mice used throughout this study, including BALB/c,
C57BL/6, and NOD, were raised and housed in strictly con-
trolled specific pathogen–free conditions.
 
Flow Cytometry.
 
Cell suspensions from thymus and spleen
were  prepared and stained at 4
 
8
 
C in PBS containing 1% BSA and
0.1% azide, after blocking Fc
 
g
 
 receptors by incubation with 2.4G2
and aggregated human IgG. For thymocytes, four-color staining was
performed with PE-conjugated anti-CD8 (Caltag Laboratories, Inc.,
San Francisco, CA), Red 613–conjugated anti-CD4 (GIBCO BRL,
Gaithersburg, MD), FITC-conjugated anti–TCR-
 
a
 
/
 
b
 
 (H57 mAb),
biotinylated anti-NK1.1 (PK 136; PharMingen, San Diego, CA),
and streptavidin-allophycocyanin (SA-APC; PharMingen). For
splenocytes, two-color staining was performed using PE-conjugated
anti-CD4 (Caltag Laboratories, Inc.) and Red 613–conjugated anti-
CD8. For three-color staining, biotinylated anti-NK1.1, FITC-
conjugated anti-
 
a
 
/
 
b
 
, PE-conjugated anti–Thy-1 (30H12 mAb), and
SA-APC were used. Cells were analyzed on a FACSCalibur
 
Ò
 
(Becton Dickinson, Mountain View, CA) using CellQuest software.
 
Cytokine Release after CD3 Stimulation.
 
For in vivo CD3
stimulation, 4 
 
m
 
g of anti-CD3 mAb 2C11 was injected intrave-
nously. Spleens were removed 90 min later, reduced to single-cell
suspensions, and cultured, without further stimulation, at a den-
sity of 10
 
7
 
 cells in 1 ml of complete medium (RPMI containing
10% FCS, glutamine, 2-ME, penicillin-streptomycin) for 2 h to
measure IL-4 release in the culture supernatants. For other cyto-
kines (IFN-
 
g
 
, IL-2, and IL-10), splenocytes were incubated at the
same density for 24 h in anti-CD3–coated plates. IL-4 was quan-
titated in a bioassay using the IL-4–dependent CT-4S cell line
(25) in the presence of anti–IL-2 mAb S4B6 at 10 
 
m
 
g/ml, or in
an ELISA using mAbs 11B11 (26) and BVD6 (DNAX Research
Institute, Palo Alto, CA). IFN-
 
g
 
, IL-2, and IL-10 were measured
by ELISAs using mAbs AN18, R46A2, 1A12, 5H4, JES5, and
SXC1 (the last five mAbs were a gift from DNAX Research In-
stitute). Recombinant mouse IL-4, IL-10, and IFN-
 
g
 
 were from
R & D Systems (Abingdon, Oxfordshire, UK), and IL-2 was
from Genzyme Corp. (Cambridge, MA).
 
Serum Ig Isotype Levels.
 
Serum levels of Ig isotypes were mea-
sured by using standard sandwich ELISAs. Specific polyclonal an-
tibodies against IgG1, IgG2a, IgG2b, and IgG3 (Southern Bio-
technology Associates, Inc., Birmingham, AL) and the anti-IgE
mAb LOME (Caltag Laboratories, Inc.) were used for coating,
and alkaline phosphatase–conjugated anti-IgG (Sigma Chemical
Co., St. Louis, MO) or biotinylated anti-IgE LO-ME-2 (Biosys,
Compiègne, France) plus SA-AP (Amersham International, Les
Ulis, France) was used for detection.
 
Diabetes Incidence and Histology.
 
Females and males were
tested every week for diabetes. Overt diabetes was defined as two
consecutive positive glucosuria tests and glycemia 
 
.
 
200 mg/dl.
Glukotest and Haemoglukotest were purchased from Boehringer
Mannheim (Mannheim, Germany). For cyclophosphamide-
induced diabetes, 10-wk-old males were injected once intraperito-
neally with 300 mg/kg cyclophosphamide (Sigma Chemical Co.)
diluted to 30 mg/ml in PBS immediately before injection. Insuli-
tis was evaluated on noncontiguous 4-
 
m
 
m-thick sections of pan-
creas from 11–12-wk-old females. Sections were stained with he-
matoxylin and eosin. Insulitis was scored according to the degree
of infiltration.
 
Transfer Experiments.
 
Recipients were 4–5-wk-old scid NOD
mice. According to the type of experiment, diabetogenic spleno-
cytes were obtained from overtly diabetic mice or from old
asymptomatic donors. After red cell lysis in NH
 
4
 
Cl, the percentage
of T cells was determined by immunofluorescence staining, and 
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the equivalent of 1 or 2 
 
3 
 
10
 
6
 
 T cells were injected intrave-
nously, alone or with other lymphocyte populations. Splenocytes
from transgenic mice of line 86 C
 
a
 
2
 
/
 
2
 
 were further depleted of B
cells by panning on anti-IgM–coated plates. Immunofluorescence
staining was performed, and the equivalent of 10
 
7
 
 T cells (
 
a
 
/
 
b
 
1
 
)
were coinjected with diabetogenic T cells (200 
 
m
 
l/mouse). In
one experiment, the same number of control cells (splenocytes
from C
 
a
 
2
 
/
 
2
 
 mice) were injected. In transfer experiments, spleno-
cytes were prepared from three groups of female NOD mice:
nondiabetic transgenic, control littermates of 
 
.
 
52 wk of age, or
overtly diabetic mice. Spleens from mice of each group were
pooled, red cells were lysed, and B cells were partially removed by
panning on anti-IgM–coated plates. The percentage of T cells in
each population was determined by immunofluorescence staining
and varied between 53 and 75%. The equivalent of 2 
 
3 
 
10
 
6
 
 T cells
were injected intravenously into scid NOD females. The same ex-
periment was performed with splenocytes from old transgenic
nondiabetic males, using diabetic males as positive controls.
 
Statistical Analysis.
 
Differences in cytokine production were
analyzed using Student’s 
 
t
 
 test. Diabetes incidence was studied us-
ing the log rank test.
 
Results
 
V
 
a
 
14-J
 
a
 
281 Transgenic NOD Mice Have an Increased
Number of NK1.1
 
1 T Cells. Although  a/b DN thy-
mocytes have often been used as a reliable source of NK T
cells (23), they are heterogenous in their composition and
contain both NK1.11 and NK1.12 lymphocytes. As illus-
trated in Fig. 1, NK1.11 T cells represent roughly 1/3
(27%) of the a/b DN compartment. The remaining 2/3
include Va14-positive and -negative cells as well as CD1
nonrestricted lymphocytes, clearly identified in CD1 knock-
out mice (Park, S.-H., and A. Bendelac, unpublished re-
sults). Thus, in order to evaluate precisely the role of NK T
cells in the pathogenesis of diabetes, we generated a panel
of NOD founders expressing the invariant TCR a chain of
NK T cells, using the Va14-Ja281 construct validated in
C57BL/6 mice (22). As NOD mice do not express the
NK1.1 allele, founder lines were first screened by immu-
nofluorescence analysis of lymphoid organs for an increased
percentage of DN thymocytes expressing a Vb8-biased
repertoire (data not shown). By crossing with NK1.1 con-
genic NOD mice, we confirmed that the six selected trans-
genic lines had an increased frequency of NK1.11 T cells in
the thymus and spleen (Fig. 2, and Table 1). In the 6 lines,
the increase in NK1.11 a/b T cell numbers varied from
2.5- to 6.2-fold in the spleen. Interestingly, NK1.11 T cells
were mainly of the DN phenotype, whereas the remainder
expressed CD4 (Fig. 2). The transgenic line 86 (with the
highest frequency of NK1.11 T cells) was further crossed
with a Ca2/2 NOD mouse to eliminate endogenous a
chain rearrangements. Surprisingly, the percentage of
NK1.11 T cells was not significantly modified, suggesting
that the pairing of the transgenic a chain with various b
chains allowed the development of a large number of T
cells without the NK1.1 marker. As described previously,
NK1.11 T cells in all six lines expressed intermediate levels
of TCR and were positive for the two activation markers
CD44 and CD122 (data not shown). These results showed
that enforced expression of the Va14-Ja281 chain in
Figure 1. NK T cells represent only a fraction of a/b CD42CD82
DN thymocytes. Thymocytes from an 8-wk-old NOD NK1.1 mouse
were quadruply stained with mAbs anti-CD4, anti-CD8, anti–TCR-a/b,
and anti-NK1.1. Percentage values are relative to the gated DN popula-
tion.
Figure 2. Increased expression of NK1.11 T cells in Va14-Ja281
transgenic mice. (A) Thymocytes from an 8-wk-old Va14-Ja281 trans-
genic (line 86) NOD NK1.1 mouse and a littermate control were qua-
druply stained with mAbs anti-CD4, anti-CD8, anti–TCR-a/b, and
anti-NK1.1. Percentage values are relative to the whole thymocyte popu-
lation. (B) Splenocytes from a 12-wk-old Va14-Ja281 transgenic (line
86) NOD NK1.1 mouse, a littermate control, and a C57BL/6 mouse
were either dually stained with anti-CD4 and anti-CD8, or triply stained
with anti–Thy-1, anti–TCR-a/b, and anti-NK1.1. Percentages are rela-
tive to the whole splenocyte population.1834 NK T Cells and NOD Diabetes
NOD mice leads to a substantial increase in NK1.11 T cells
in both the thymus and periphery.
Increased Cytokine Production by Splenocytes after CD3 Stim-
ulation. We then measured IL-4 release after in vivo stim-
ulation by anti-CD3 mAb in 10-wk-old transgenic and
wild-type female littermates. This assay rigorously reflects
NK T cell activity (27). As shown in Fig. 3, splenocytes
from the six transgenic lines released higher amounts of IL-4
than those from control NOD mice. In three of the lines,
levels were comparable to those obtained with BALB/c
and C57BL/6 mice, i.e., four to six times the amount re-
leased by control NOD mice. In the other three lines, the
increase was 13–25-fold relative to the amount released by
control NOD mice. Interestingly, the increase in IL-4 pro-
duction ran parallel to the increase in NK1.11 T cell num-
bers in the six transgenic lines. As NK T cells can produce
cytokines other than IL-4 and influence the production of
various cytokines by other T cells (16), we also measured
the production of IFN-g, IL-2, and IL-10 after in vitro
culture on anti-CD3–coated plates. Splenocytes from lines
95, 78, and 86 released slightly more (1.4–1.8-fold) IFN-g
than controls, but the differences were not statistically sig-
nificant. IL-2 production by splenocytes from the six lines
was decreased relative to controls, whereas IL-10 produc-
tion was slightly increased. These data clearly showed that
NK T cells in the transgenic mice were functional.
In all six lines, the enhancement of IL-4 production after
in vivo triggering by anti-CD3 antibody was already ob-
servable at 3 wk of age (data not shown), indicating that
functional NK T cells are present at a higher frequency in
the spleen of transgenic mice before islet infiltration begins.
Selective Increase in Th2-associated Ig Isotypes. IgE and IgG1
production is a characteristic feature of Th2 responses. If
overexpression of NK T cells indeed results in higher pro-
duction of IL-4, which in turn can shift the immune system
towards a Th2 phenotype, increased Th2-controlled Ig iso-
type serum levels should be found. As shown in Fig. 4 A,
transgenic NOD mice from line 86 had elevated levels of
serum IgE (4-fold) and IgG1 (1.3-fold) compared with con-
trol littermates, whereas the levels of the other isotypes were
unchanged. All transgenic lines had increased levels of serum
IgE compared with control NOD mice, and the increase in
serum IgE levels was strongest in line 86, which expressed
the largest number of NK T cells (Fig. 4 B). Interestingly,
line 86 Ca2/2 exhibited even higher serum IgE levels. Gen-
erally, IL-4 and IgE levels were lower in male transgenics
than in their female counterparts (data not shown).
Incidence of Spontaneous Diabetes in Females and Males.
The incidence of diabetes in females was decreased in three
lines, corresponding to those with the highest NK T cell
numbers (Fig. 5 A). The level of protection in each line
matched the increase in NK T cell numbers and in the IL-4
Table 1. T Cell Subsets in the Spleen of the Various Transgenic Lines (Females $6 wk of age)
Mice Cell no. a/b1*‡ a/b1 CD41*‡ a/b1 CD81*‡ a/b1 DN*‡ a/b1 NK1.11‡ a/b1 NK1.11/a/b1§
31026 6 SD % % % % % %
NOD 113 6 34 38.3 6 6.1 25.5 6 4.4 8.4 6 1.5 4.4 6 1.9 0.4 6 0.2 1.0
(n 5 64) (n 5 11)
Tg A14-14 95 6 33 33.1 6 7.0 16.1 6 2.2 5.2 6 1.6 11.8 6 3.4 1.0 6 0.1 3.0
(n 5 7) (n 5 3)
Tg A14-36 101 6 34 36.0 6 2.4 18.0 6 1.4 6.0 6 1.1 12.0 6 2.5 1.2 6 0.1 3.3
(n 5 7) (n 5 4)
Tg A14-10 87 6 23 36.3 6 7.8 15.8 6 2.7 5.7 6 1.6 14.8 6 4.9 1.4 6 0.3 3.9
(n 5 5) (n 5 2)
Tg A14-95 89 6 31 31.1 6 0.6 14.7 6 1.5 4.2 6 0.3 12.2 6 1.7 1.9 6 0.7 6.1
(n 5 19) (n 5 2)
Tg A14-78 101 6 43 32.2 6 1.9 14.1 6 1.0 3.5 6 0.4 14.6 6 1.5 2.1 6 0.2 6.5
(n 5 21) (n 5 3)
Tg A14-86 74 6 28 31.8 6 1.0 13.3 6 0.3 3.3 6 0.6 15.2 6 1.1 2.5 6 1.4 7.9
(n 5 26) (n 5 14)
Tg A14-86 89 6 43 24.4 6 3.7 5.7 6 1.0 1.9 6 0.4 16.8 6 3.0 1.9 6 0.5 7.8
CaKO (n 5 5) (n 5 8)
C57BL/6 73 6 8 32.4 6 2.7 18.4 6 1.2 12.3 6 0.7 1.7 6 0.8 0.9 6 0.2 2.8
(n 5 8) (n 5 9)
Tg, transgenic. KO, knockout.
*n 5 3.
‡Percent of the cell population in the whole spleen.
§Percent of the ratio.1835 Lehuen et al.
burst. Line 86 was the best protected (P , 0.0001, log rank
test), followed by line 78 (P 5 0.004) and line 95 (P 5 0.04).
The incidence of diabetes in lines 10, 14, and 36 (interme-
diate numbers of NK T cells) was not significantly different
from that in control NOD mice. The incidence rates were
compared with those in transgene-negative littermates of
all six lines, and to that in a larger group of NOD mice
housed in the same facilities (data not shown). Among
males, only those from line 86 (Fig. 5 B) showed a reduced
incidence of the disease (P 5 0.04). Males from lines 95
and 78 had the same incidence as their control littermates.
Histologic studies were performed on the pancreas of 11–
12-wk-old females of line 86 and their negative littermates
(data not shown). Islet infiltration was present in both
groups but was less invasive in transgenic than in control
mice, resulting in a slightly lower percentage of healthy is-
lets in the latter (39 vs. 52%). Therefore, histological find-
ings were consistent with clinical findings.
Figure 3. Cytokine produc-
tion by splenocytes from Va14-
Ja281 transgenic mice. Levels of
cytokines produced in vitro by
splenocytes after in vivo anti-CD3
stimulation. (A) IL-4 production
was measured in supernatants
after 2 h in culture without fur-
ther stimulation, and (B) IFN-g,
(C) IL-2, and (D) IL-10 produc-
tion was measured after 24 h in
culture on anti-CD3–coated
plates. Females from 6 transgenic
lines, line 86 Ca2/2, 20 negative
NOD littermates, and controls
(BALB/c and C57BL/6) were
analyzed at 10 wk of age. Each
point represents an individual
mouse; filled symbols, control
mice; open symbols, transgenic
NOD mice.1836 NK T Cells and NOD Diabetes
Discussion
Enforced expression of the Va14-Ja281 TCR a chain
in NOD mice results in overexpression of NK T cells as re-
ported previously in C57BL/6 mice (16). This augmenta-
tion can be visualized phenotypically in the spleen and thy-
mus by measuring the percentage of DN NK1.11 a/b T
cells, and functionally by the burst of IL-4 release shortly
after an intravenous injection of anti-CD3 mAb. The sig-
nificant increase in serum IgE provides further confirma-
tion that NK T cells, which can produce massive amounts
of IL-4 shortly after triggering of their TCR, promote the
production of Th2-controlled Ig isotypes in vivo, with no
particular stimulation of the immune system. It is not cer-
tain that the subset of a/b DN spleen cells, which was in-
creased markedly in all the transgenic lines, corresponds en-
tirely to NK T cells. a/b DN cells can be found in various
TCR transgenic mice (28, 29), even when TCR trans-
genes are not specific for CD1 and are not related to NK T
cells. We prefer a more conservative definition of NK T
cells, i.e., cells which are positive for the NKRP1 receptor
(NK1.1) and a/b TCR. Even with this definition, the in-
crease in NK T cells remained impressive in our Va14-
Ja281 transgenic mice (7.9% of all a/b cells vs. 1% in con-
trols).
Interestingly, the increase in NK T cell numbers in the
spleen was variable in the six transgenic lines analyzed in
this study, ranging from 3 to 7.9%. The production of this
panel of transgenic lines allowed us to determine if the in-
crease in NK T cell numbers up to and beyond the levels in
BALB/c and C57BL/6 mice modified the incidence of di-
abetes. We found that the three transgenic lines (lines 36,
14, and 10), which expressed 2.5–3.5 times more NK T
cells than control NOD mice, produced similar amounts of
IL-4 on in vivo stimulation by anti-CD3 mAb to those
found in BALB/c and C57BL/6 mice, and elevated serum
IgE levels compared with NOD mice. However, these
transgenic lines had a similar incidence of diabetes as wild-
type NOD mice. Conversely, the other three transgenic
Figure 4. Increased levels of Th2-con-
trolled Ig isotypes in Va14-Ja281 transgenic
mice. Serum levels of Ig isotypes were mea-
sured in 10–16-wk-old females. The average
level of each isotype in control female NOD
mice is set arbitrarily at 1 U/ml. (A) Serum
Ig isotypes of female transgenics from line 86
and their negative littermates. (B) Serum IgE
in females from the six Va14-Ja281 trans-
genic lines, line 86 Ca2/2, NOD, BALB/c,
and C57BL/6 mice.
Diabetes Incidence in Males after Cyclophosphamide Injection.
Diabetes can be accelerated in 10-wk-old NOD males by a
single injection of cyclophosphamide (300 mg/kg). In two
consecutive experiments, males of line 86 appeared to be
resistant to diabetes acceleration by cyclophosphamide,
whereas males from line 36 (intermediate NK1.11 T cell
numbers) developed diabetes at the same frequency as
wild-type NOD controls (Fig. 5 C). This suggested that
resistance to cyclophosphamide-induced diabetes was only
achieved when NK T cells reached a given threshold
count.
Adoptive Transfer. To gain further insight into the
mode of action of NK T cells, enriched populations of
splenocytes from Ca2/2 transgenic mice belonging to line
86 were coinjected with 2 3 106 diabetogenic T cells. The
addition of such a population significantly enriched in NK
T cells delayed the development of diabetes in scid NOD
recipients, whereas a control population of Ca2/2 but
non–Va14-Ja281 transgenic splenocytes had no effect (Fig.
6 A). Interestingly, when the number of diabetogenic T
cells was reduced to 106, diabetes transfer was more effi-
ciently inhibited, pointing to a quantitative relationship be-
tween pathogenic cells and actively protecting cells (Fig. 6 B).
To determine if mice of transgenic line 86 which es-
caped overt diabetes nevertheless harbored diabetogenic T
cells, splenocytes from 1-yr-old clinically silent transgenic
donors were transferred into NOD scid recipients. For
comparison, splenocytes from nondiabetic wild-type litter-
mates and splenocytes from recently diagnosed diabetic
NOD mice were injected in parallel. The results demon-
strated the presence of diabetogenic T cells in transgenic
mice. Splenocytes from Va14-Ja281 transgenic mice were
as efficient as those from diabetic NOD mice in inducing
diabetes in scid recipients (Fig. 7 A). Similar results were
obtained when the experiment was performed with spleno-
cytes from transgenic males of line 86 (Fig. 7 B). Thus, dia-
betogenic T cells develop normally in diabetes-free trans-
genic mice but are actively suppressed by NK T cells.1837 Lehuen et al.
lines, with larger increases in NK T cell numbers, mani-
fested, at least in females, a significantly reduced disease in-
cidence compared with their control littermates. This was
even more marked in the case of cyclophosphamide-accel-
erated disease. Thus, against a polygenic background con-
ducive to diabetes, the disease incidence can be reduced
only by raising the number of functional NK T cells.
The possibility that the protection achieved in three in-
dependent lines of NOD transgenic mice could be due to
insertional interference of the transgene on genes required
for diabetes development is unlikely. More importantly,
defects such as incomplete T cell repertoire build-up, crip-
pled T cell ontogeny, and abnormal subset development,
which could possibly account for the reduced diabetes inci-
dence in TCR a chain transgenic mice, were excluded by
transfer experiments. First, cotransfer of Va14-Ja281 T
cells with diabetogenic splenocytes from nontransgenic dia-
betic female NOD mice prevented the development of di-
abetes in scid recipients. This suggests that Va14-Ja281 T
cells can suppress pathogenic autoreactive T cells. Second,
in lines 95 and 78, males clearly generated sufficient
amounts of diabetogenic T cells to cause clinical disease.
Only females were partially protected in these lines. Third,
splenocytes from old (.1 yr) nondiabetic Va14-Ja281
transgenic females and males belonging to line 86 con-
tained diabetogenic T cells, as revealed by transfer into
NOD scid mice. Surprisingly, these splenocytes were as ef-
ficient at transferring diabetes as splenocytes from diabetic
mice. This suggests that diabetogenic T cells accumulate in
the spleen of aging transgenic mice and are inhibited by the
increased number of NK T cells. After transfer to scid re-
cipients, diabetogenic splenocytes seem to escape from im-
munoregulation by NK T cells, probably because the ratio
between protective and pathogenic cells is modified in the
scid recipients. The importance of the ratio between the
two populations was clear in the cotransfer experiments
Figure 5. Overexpression of NK T cells protects against diabetes de-
velopment. (A) Incidence of spontaneous diabetes in Va14-Ja281 trans-
genic females of lines 86, 78, 95, and 10 plus 14 plus 36, compared with
negative littermates. The incidence in the latter three lines was not signif-
icantly different from each other, and values were thus pooled. (B) Inci-
dence of spontaneous diabetes in males from lines 95, 78, and 86 com-
pared with negative littermates. (C) Diabetes incidence after one injection
of cyclophosphamide (CY; 300 mg/kg) in 10-wk-old males from Va14-
Ja281 transgenic line 86 and line 36 and their negative littermates.
Figure 6. Active protection by cotransfer of NK T cell–enriched pop-
ulations from transgenic donors. NOD scid males (5-wk-old) were in-
jected intravenously with a mixture of cells containing diabetogenic T
cell–enriched lymphocytes from freshly diagnosed diabetic mice (2 3 106
in A, 106 in B), and 107 T cell–enriched lymphocytes from Ca2/2 trans-
genic mice and the same number of splenocytes from Ca2/2 nontrans-
genic mice. T cells were purified by panning on anti-m–coated plates; the
percentage of T cells in each population varied from 75 to 80%.1838 NK T Cells and NOD Diabetes
(Fig. 6). Altogether, these results show that (a) TCR a
chain transgenic mice develop a T cell repertoire with dia-
betogenic precursors, and that (b) Va14-Ja281 T cells can
regulate diabetogenic T cells.
The implication of NK T cells in autoimmune condi-
tions does not seem to be restricted to NOD mice. Human
IDDM patients have a reduced number of Va24-JaQ1
DN peripheral blood lymphocytes, and these cells show
deficient IL-4 production (13). In other models of autoim-
munity, such as lpr/lpr, NZB, and BxW lupus mice, there
is a decrease in NK T cell numbers at the onset of disease
(30, 31). SJL mice, which have a profound deficiency in
NK T cells, are highly susceptible to experimental allergic
encephalomyelitis, a Th1-mediated autoimmune disease (32).
To explain the impact of NK T cells on diabetes devel-
opment, we postulate that these cells induce a shift in the
balance of antiislet T cells from the pathogenic Th1 pheno-
type toward a less harmful Th2 phenotype. Our prelimi-
nary analysis of intraislet cytokine mRNA from transgenic
females of line 86 supports this view, by clearly showing a
decrease in IFN-g mRNA and an increase in IL-4 mRNA
(data not shown). This result is reminiscent of previous ob-
servations on the role of Th1 cells as inducers of diabetes,
and the protective role of IL-4. Indeed, diabetes is acceler-
ated by systemic treatment with IL-12 and delayed by sys-
temic treatment with anti–IFN-g mAb, IL-12 antagonist
(p40)2, or IL-4, or by local islet expression of IL-4 in insu-
lin promoter–IL-4 transgenic mice (3–6, 33, 34). This local
action of NK T cells will require further investigation. It is,
for instance, possible that NK T cells are turned on locally
by increased expression of their ligand, CD1. Alternatively,
other signals initiated by the inflammatory process, such as
B7.1 and B7.2, CD40, or even more upstream signals such
as those postulated in the case of necrotic cell death (35),
may locally alert NK T cells. Like other members of the in-
nate immune system, NK T cells may respond to a series of
ill-defined predetermined stimuli via TCR and NK recep-
tors (16, 36, 37). In conclusion, our observations support
the particular role of NK T cells in immunoregulation and
their potential to control autoimmune disorders.
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